Results 151 to 160 of about 5,542 (243)

The economic pressures for biosimilar drug use in cancer medicine [PDF]

, 2012
Paul Cornes
core   +1 more source

Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028. [PDF]

J Manag Care Spec Pharm
Cousin EM, Martin K, Hansen RN, Coster J, Sullivan SD.   +4 more
europepmc   +1 more source

Barriers to Biosimilar Approval: Creating Clarity Through the Publication of Product-Class Specific Guidances [PDF]

, 2016
McEnrue, Martin
core  

The Impact of Biosimilar Launch on Molecule Price and Pharmaceutical Expense: The Case of the Insulin Glargine in Italy [PDF]

Value in Health, 2017
A Tettamanti, L Cioni, C Tucci
openaire   +1 more source

Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre. [PDF]

Cureus
Sourla E, Zaheer N, Chavan R.
europepmc   +1 more source

Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization. [PDF]

Turk J Ophthalmol
Özgür A, Yeşilırmak N, İnan MA, Bağrıaçık EÜ, Özmen MC.   +4 more
europepmc   +1 more source

How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013 [PDF]

, 2015

core   +1 more source

A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea^® in Patients with Wet Age-Related Macular Degeneration. [PDF]

Ophthalmol Ther
Bansal M, Singh P, Mehta RK, Laul RS, Rana P, Shah U, Vohra R, Desai S, Bhomaj S, Patwardhan S, Manoher JM, Sapar A, Parwal S, Amabde AK, Shroff R, Natesh S, Biswas RK, D LR, Sinha BP, C K M, Patel E, Kamble A, Bhende P, Patil S, Shah A, Narula R, Kumari B, Bathula L, Kirtane S, Darji B, Doshi M, Parmar D.   +31 more
europepmc   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study. [PDF]

Clin Ophthalmol
Chakraborty D, Sinha TK, Sinha S, Biswas RK, Maiti A, Nandi K, Rungta D, Bhattacharya R.   +7 more
europepmc   +1 more source

Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials. [PDF]

Clin Exp Med
Shakibaei F, Malekshahi S, Heidari N, Heidari A.   +3 more
europepmc   +1 more source